Ett andetag för klimatet

Expert opinion paper: Improving asthma control with effective maintenance therapy can reduce both the risk of exacerbations and greenhouse gas emissions

Expert opinion paper

Improving asthma control with effective maintenance therapy can reduce both the risk of exacerbations and greenhouse gas emissions.

Literature review on inhaler selection and device switching — Switching to an Easyhaler device may improve asthma and COPD control without causing additional risks

Lavorini F, et al. 2021 Pulmonary Therapy 

Budesonide/Formoterol Easyhaler: performance under simulated real-life conditions

Haikarainen et al. 2017. Pulm Ther

In vitro flow rate dependency of delivered dose and fine particle dose of Salmeterol/Fluticasone Propionate Easyhaler® and Seretide Diskus® with patient flow rates collected in a randomized controlled trial

Jõgi et al. 2018. JAMP

The Easyhaler® provides accurate and consistent dosing across varying patient inhalation flow rates

Technical review: Easyhaler® provides accurate and consistent dosing across varying patient inhalation flow rates.

Symposium Towards a predict and prevent approach in obstructive airway diseases

Enligt forskning är det nyttigt för KOL-patienter att sjunga – 3 positiva sätt att lindra KOL-symtom

Clinical effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes

Tamási et al. 2018. Adv Ther

Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice

Pirozynski et al. 2017. Adv Ther

Combating climate change with a sustainable inhaler

Wilkinson et al. 2019 BMJ Open

Highlights from Orion’s webinar: Sustainable care of asthma and COPD — partnership between patients and professionals (April 26, 2022)

Orion Pharma åtar sig att bli koldioxidneutralt senast 2030

Events